Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Two novel radioligands, N,N-dimethyl-2-(2-amino-4-methoxyphenylthio) b enzylamine (DAPP) and (N,N-dimethyl-2-(2-amino-4-cyanophenylthio) benzylamine (D ASB), were radiolabeled with carbon-11 and evaluated as in vivo probes of the serotonin transporter (SERT) using positron emission tomography (PET). Both compounds are highly selective, with nanomolar affinity for the serotonin transporter and micromolar affinity for the dopamine and norepinephrine transporters. Six volunteers were imaged twice, once with each of the two radioligands. Both ligands displayed very good brain penetration and selective retention in regions rich in serotonin reuptake sites. Both had similar brain uptake and kinetics, but the cyano analogue, [11C]DASB, had a slightly higher brain penetration in all subjects. Plasma analysis revealed that both radiotracers were rapidly metabolized to give mainly hydrophilic species as determined by reverse-phase high-performance liquid chromatography. Inhibition of specific binding to the SERT was demonstrated in three additional subjects imaged with [11C]DASB following an oral dose of the selective serotonin reuptake blocker citalopram. These preliminary studies indicate that both these substituted phenylthiobenzylamines have highly suitable characteristics for probing the serotonin reuptake system with PET in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a total of 16 articles (reporting on 17 unique studies) were included [17–19, 28–40].”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [34]
In the citing paper
“One study reported overall alcohol consumption during the study period [35], and seven studies controlled for present or past alcohol problems or abuse [17, 28, 30, 33, 34, 39, 40].”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [34]
Citations
Cites
Wilson, A. A., Ginovart, N., Schmidt, M., Meyer, J. H., Threlkeld, P. G., & Houle, S. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000079i · Cited by 249
Self-citationRadiotracer synthesis from [11C]-iodomethane: a remarkably simple captive solvent method
Wilson, A. A., Garcia, A., Jin, L., & Houle, S. (2000) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(00)00132-3 · Cited by 201
Self-citationSzabo, Z., Kao, P. F., Scheffel, U., Suehiro, M., Mathews, W. B., Ravert, H. T., Musachio, J. L., Marenco, S., Kim, S. E., Ricaurte, G. A., et al. (1995) · Synapse · doi:10.1002/syn.890200107 · Cited by 170
Laruelle, M., Vanisberg, M.-A., & Maloteaux, J.-M. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90198-9 · Cited by 166
High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue
Ba¨ckstro¨m, I., Bergstro¨m, M., & Marcusson, J. (1989) · Brain Research · doi:10.1016/0006-8993(89)90511-8 · Cited by 162
Wilson, A. A., & Houle, S. (1999) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/(sici)1099-1344(19991230)42:13<1277::aid-jlcr284>3.0.co;2-q · Cited by 71
Self-citationSmith, D. F. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00042-5 · Cited by 33
Acton, P. D., Kung, M., Mu, M., Plöessl, K., Hou, C., Siciliano, M., Oya, S., & Kung, H. F. (1999) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050459 · Cited by 33
Cited by
Items 201–299 of 299
Genetic contributions to brain serotonin transporter levels in healthy adults
Bruzzone, S. E. P., Nasser, A., Aripaka, S. S., Spies, M., Ozenne, B., Jensen, P. S., Knudsen, G. M., Frøkjær, V. G., & Fisher, P. M. (2023) · Scientific Reports · doi:10.1038/s41598-023-43690-x · Cited by 18
Melasch, J., Rullmann, M., Hilbert, A., Luthardt, J., Becker, G., Patt, M., Stümvoll, M., Blüher, M., Villringer, A., Arélin, K., et al. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.63 · Cited by 8
Molecular Imaging of Extrapyramidal Movement Disorders
Frey, K. A. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.007 · Cited by 8
Zhou, Y., Ou, Y., Ju, Z., Zhang, X., Zheng, L., Li, J., Sun, Y., & Liu, X. (2020) · Annals of Nuclear Medicine · doi:10.1007/s12149-020-01495-2 · Cited by 9
Inhibition of serotonin transport by (+)McN5652 is noncompetitive
Hummerich, R., Schulze, O., Rädler, T., Mikecz, P., Reimold, M., Brenner, W., Clausen, M., Schloss, P. D., & Buchert, R. (2006) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2005.12.009 · Cited by 8
“Most widely used are the tracers [I]h-CIT [5–9], [C] (+)McN5652 [10–13] and [C] DASB [14–17].”
PET radiopharmaceuticals for neuroreceptor imaging
Ametamey, S. M., & Schubiger, P. A. (2006) · Nuclear Science and Techniques · doi:10.1016/s1001-8042(06)60028-6 · Cited by 7
Guo, Y., Chen, X., Jia, H., Ji, X., & Liu, B. (2008) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2008.06.009 · Cited by 7
Progress in PET Imaging of the Norepinephrine Transporter System
Ding, Y. (2014) · Springer eBooks · doi:10.1007/978-3-642-42014-6_19 · Cited by 6
Yoshimura, Y., Kikuchi, M., Saito, D. N., Hirosawa, T., Takahashi, T., Munesue, T., Kosaka, H., Naito, N., Ouchi, Y., & Minabe, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-71254-w · Cited by 6
Monoamine Oxidase A and Serotonin Transporter Imaging with Positron Emission Tomography
Meyer, J. H. (2014) · Springer eBooks · doi:10.1007/978-3-642-42014-6_25 · Cited by 7
Self-citationLigand Tracer Kinetics: Theory and Application
Slifstein, M., Frankle, W. G., & Laruelle, M. A. (2004) · Springer eBooks · doi:10.1007/978-3-642-18773-5_6 · Cited by 6
New fluoro-diphenylchalcogen derivatives to explore the serotonin transporter by PET
Vercouillie, J., Deuther‐Conrad, W., Scheunemann, M., Emond, P., Fischer, S., Funke, U., Steinbach, J., Guilloteau, D., & Brust, P. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.02.082 · Cited by 6
Neuroimaging Biomarkers in Parkinson’s Disease
Holmes, S. E., & Tinaz, S. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-69491-2_21 · Cited by 6
Liu, F., Zhu, L., Choi, S., Plöessl, K., Zha, Z., & Kung, H. F. (2018) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3626 · Cited by 5
Madsen, J., Elfving, B., Andersen, K. V., Martiny, L., & Knudsen, G. M. (2004) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.820 · Cited by 5
Taylor, O., Laeken, N. V., Vos, F. D., Polis, I., Bosmans, T., Goethals, I., Achten, R., Dobbeleir, A. A., Vandermeulen, E., Baeken, C., et al. (2015) · BMC Veterinary Research · doi:10.1186/s12917-015-0622-3 · Cited by 5
“In human studies, ratios of radioactivity within the ROIs to that in the cerebellum were calculated using data from 55 to 90 min after injection of the radiotracer [17, 18].”
BackgroundMethodBuchert, R., Varga, J., & Mester, J. (2004) · Nuclear Medicine Communications · doi:10.1097/00006231-200405000-00005 · Cited by 5
Positron Emission Tomography Agents for Central Nervous System Drug Development Applications
Mason, N. S., & Mathis, C. A. (2005) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(05)40004-4 · Cited by 4
Quantifying serotonin transporters by PET with [ 11 C]‐DASB before and after interferon‐α treatment
Shapiro, P. A., Sloan, R. P., Deochand, C., Franceschi, A. M., DeLorenzo, C., Mann, J. J., & Parsey, R. V. (2014) · Synapse · doi:10.1002/syn.21766 · Cited by 4
“Specifically, we measured serotonin transporter binding using PET and [(11)C]-DASB, a selective serotonin transporter ligand (Houle et al., 2000; Wilson et al., 2000) in four brain regions of interest (ROIs), the MID, ACN, VST, and HIP, before and after 8 weeks of IFN-a treatment.”
MethodProgress in PET Imaging of the Norepinephrine Transporter System
Ding, Y. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_20 · Cited by 7
Biodistribution and dosimetry of 123I-mZIENT: a novel ligand for imaging serotonin transporters
Nicol, A., Krishnadas, R., Champion, S., Tamagnan, G. D., Stehouwer, J. S., Goodman, M. M., Hadley, D. M., & Pimlott, S. L. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2056-x · Cited by 4
Oh, M., Brumberg, J., Sossi, V., & Varrone, A. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268233 · Cited by 3
Radiotracers for the Central Serotoninergic System
Mangeant, R., Dubost⧫, E., Cailly, T., & Collot, V. (2022) · Pharmaceuticals · doi:10.3390/ph15050571 · Cited by 4
Hwang, K.-H., Lee, H., & Sung, Y. H. (2023) · Current Medical Imaging Formerly Current Medical Imaging Reviews · doi:10.2174/1573405619666230124142725 · Cited by 3
Molecular neuroimaging of the serotonergic system with Positron Emission Tomography
Silberbauer, L., James, G. M., Spies, M., Michenthaler, P., Kranz, G. S., Kasper, S. F., & Lanzenberger, R. R. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00009-8 · Cited by 3
A radiometabolite study of the serotonin transporter PET radioligand [11C]MADAM
Gourand, F., Emond, P., Bergström, J. P., Takano, A., Gulyás, B. Z., Guilloteau, D., Barré, L., & Halldin, C. (2014) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2014.03.022 · Cited by 3
In-vivo serotonin transporter availability and somatization in healthy subjects
Bresch, A., Rullmann, M., Luthardt, J., Arélin, K., Becker, G., Patt, M., Lobsien, D., Baldofski, S., Drabe, M., Zeisig, V., et al. (2016) · Personality and Individual Differences · doi:10.1016/j.paid.2016.01.042 · Cited by 3
Laeken, N. V., Taylor, O., Polis, I., Neyt, S., Kersemans, K., Dobbeleir, A. A., Saunders, J. H., Goethals, I., Peremans, K. Y., & Vos, F. D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148943 · Cited by 3
Nuclear Medicine Imaging Tracers for Neurology
Elsinga, P. H. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_1 · Cited by 4
Serotonin receptor imaging by 18F-PET
Billard, T., Liger, F., & Verdurand, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812733-9.00013-1 · Cited by 4
Synthesis and characterization of 18F‐IDAM as a pet imaging agent for serotonin transporters
Oya, S., Choi, S., Hou, C., KUNG, M. ‐., Acton, P. D., Shiue, C. Y., & Kung, H. F. (2001) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.2580440106 · Cited by 3
Wellsow, J., Kovar, K., & Machulla, H. (2002) · PubMed · Cited by 17
Genetic, epigenetic, and environmental factors in serotonin-associated disease condition
Friedel, E., & Heinz, A. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00047-5 · Cited by 4
Monoamine Oxidase A and Serotonin Transporter Imaging with Positron Emission Tomography
Meyer, J. H. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_26 · Cited by 2
Self-citationCuomo, A., Barillà, G., Cattolico, M., Pardossi, S., Mariantoni, E., Koukouna, D., Carmellini, P., & Fagiolini, A. M. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2333394 · Cited by 3
“For optimal therapeutic intervention in major depressive disorder (MDD), 5-HT transporter occupancy of ≥80% is targeted [12,13], underscoring the importance of adjusting vortioxetine doses in patients who don’t respond to initial doses: as close to the maximum as possible, up to 20 mg/day.”
BackgroundGenetic, Epigenetic and Environmental Factors in Serotonin Associated Disease Condition
Friedel, E., & Heinz, A. (2010) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(10)70108-9 · Cited by 3
Chapter 26. PET ligands for assessing receptor occupancy in vivo
Burns, H. D., Hamill, T. G., Eng, W., & Hargreaves, R. (2001) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(01)36066-9 · Cited by 2
Annex C Biokinetic models and dose tables
(2008) · Annals of the ICRP · doi:10.1016/j.icrp.2008.08.005 · Cited by 2
“…OMeWAY-100634 9 0.1 1 Human plasma clearance data Osman et al., 1996; Pike et al., 1995; Wilson et al., 1998 COWAY 3-4 0.1 0.05–3 Human plasma clearance data Houle et al., 2000a McN-5652 3 0.2 3+ No human data Szabo et al., 1999 DASB 8 0.8–1.8 No human data Houle et al., 2000b n.a., not available.”
BackgroundInfluentialIn Vivo Imaging of Neurotransmitter Systems with PET
Gulyás, B. Z., Halldin, C., & Maziere, B. (2008) · Springer eBooks · doi:10.1007/978-0-387-30382-6_3 · Cited by 2
Sephton, S. M., Zhou, X., Thompson, S., & Aigbirhio, F. I. (2019) · Synthesis · doi:10.1055/s-0039-1690522 · Cited by 2
The pattern of memory and perceptual dysfunctions in recreational ecstasy users
Brown, J. (2005) · ANU Open Research (Australian National University) · doi:10.25911/5d7a2a76705b1 · Cited by 2
Imaging technologies in drug development: Anxiety and depression
Rabiner, E. A. (2005) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2005.11.009 · Cited by 2
From the Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
Wadman, C. (2007) · Cited by 2
Lau, C., Lyndaker, A., Shah, S., Wakim, P., Mitchell, A. L., Monroe, C. L., Kim, A. J., Cropper, T., Nair, G., Snow, J., et al. (2025) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70074 · Cited by 2
“…serotonergic systems in multiple brain regions of neurocognitively and psychiatrically asymptomatic, virologically suppressed PWH on ART using two PET radioligands: [ 11 C]DASB which assesses presynaptic serotonin reuptake [14], and [ 18 F]FDOPA, which measures presynaptic dopamine synthesis [15].”
Herold, N. K., Uebelhack, K., Franke, L., Amthauer, H., Luedemann, L., Bruhn, H., FELIX, R., Uebelhack, R., & Plotkin, M. A. (2006) · Cited by 1
PET Chemistry: Radiopharmaceuticals
Roß, T. L., & Ametamey, S. M. (2010) · Springer eBooks · doi:10.1007/978-3-540-85962-8_6 · Cited by 1
Neuroimagen y neurotoxicidad inducida por MDMA (éxtasis)
McCann, U. D., & Ricaurte, G. A. (2003) · Adicciones · doi:10.20882/adicciones.456 · Cited by 1
“Notablemente, estudios PET en humanos (Houle et al., 2000) muestran que el [11C]DASB tiene unas características más apropiadas para evaluar el estado del SERT en escenarios clínicos y que el [11C]DASB puede detectar con éxito la ocupación SERT con paroxetina y citalopram (Meyer et al., 2001).”
BackgroundNuclear Medicine Imaging Tracers for Neurology
Elsinga, P. H. (2014) · Springer eBooks · doi:10.1007/978-3-642-54307-4_1 · Cited by 1
In vivo evaluation of [123I]mZIENT as a SPECT radioligand for the serotonin transporter
Batis, J. C., Barret, O., Alagille, D., Koren, A. O., Stehouwer, J. S., Cosgrove, K., Goodman, M. M., Seibyl, J. P., & Tamagnan, G. D. (2012) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2012.07.006 · Cited by 1
Park, J.-S., Lee, J.-T., Meyer, J. H., Ilankumaran, P., Han, S., & Yim, D. (2014) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2014.22.2.83 · Cited by 1
“In images obtained for measuring SERT occupancy, the bilateral striatum was chosen as the primary region of interest for analysis because [(11)C] DASB uptake is high and homogenous in the striatum[11], and absolute test-retest differences in SERT binding potential for this region are low (<10%).”
MethodSelf-citation3 In Vivo Imaging of Neurotransmitter Systems with PET
Halldin, C. (2008) · Cited by 1
Molecular Imaging of Transporters with Positron Emission Tomography
Antoni, G., Sørensen, J. C. H., & Hall, H. (2008) · Topics in medicinal chemistry · doi:10.1007/7355_2008_025 · Cited by 1
Müller, M. L. T. M., & Bohnen, N. I. (2018) · Contemporary clinical neuroscience · doi:10.1007/978-3-319-78926-2_7 · Cited by 2
Radiopharmaceuticals for Imaging the Brain
Mukherjee, J., Shi, B., NARAYANAN, T. K., Christian, B. T., & Yang, Z.-Y. (2004) · Elsevier eBooks · doi:10.1016/b978-012744482-6.50008-9 · Cited by 1
PET evaluation of central serotonergic neurotransmission in women
Jovanovic, H. (2008) · Figshare · Cited by 3
Structure‐activity relationship of analogs of adam as ligands for serotonin transporters
Choi, S., Oya, S., Hou, C., & Kung, H. F. (2001) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.2580440166 · Cited by 1
The Impact of Genetic Polymorphisms on Neuroreceptor Imaging
Willeit, M., Kasper, S. F., & Praschak-Rieder, N. (2014) · Springer eBooks · doi:10.1007/978-3-642-42014-6_6
Integrated study on the mRNA expression of the human serotonin transporter
Vijayendran, M. (2012) · doi:10.17077/etd.z7s3cof7 · Cited by 1
Molecular imaging of the serotonin system in human behaviour
Borg, J. (2007) · Figshare
Kočoska-Maraš, L. (2012) · Figshare
Eersels, J. L. H., Klok, R. P., Verbeek, J., Jonker, A. J., & Herscheid, J. D. M. (2004) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2004.01.006
PET studies of the serotonin transporter in the human brain
Lundberg, J. (2006) · Figshare
Molecular Imaging of the CNS: Drug Actions
Mueggler, T., & Rudin, M. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0134-7_13
“Currently, two structurally related PET radiotracers suitable for imaging SERT levels in the human brain are at hand: [C]N,N-dimethyl-2-2-amino-4-cyanophenylthio benzylamine ([C]DASB) (Frankle et al. 2006; Kim et al. 2006; Wilson et al. 2002; Houle et al. 2000) and [C]-N,N-dimethyl-2-(2-amino-4-methylphenylthio) benzy…”
MethodMolecular imaging of major depression
Sacher, J., & Smith, G. S. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511782091.012 · Cited by 1
SMALL MEDICAL CYCLOTRON PRODUCED RADIOISOTOPES: FROM CLASSIC TO NOVEL RADIOTRACERS
Ciucă, A., Măirean, C. P., Spac, A., Dimofte, G., & Hăncianu, M. (2019) · The Medical-Surgical Journal
Seroto-nergic and noradrenergic modulation of emotion process-ing by sing dose antidepressants
Brühl, A. B., Kaffenberger, T., & Herwig, U. (2010) · Medical Entomology and Zoology
Evidence-Based PET for Neurological Diseases
Miceli, A., Capitanio, S., Donegani, M. I., Raffa, S., Borra, A., Bauckneht, M., & Morbelli, S. D. (2020) · Springer eBooks · doi:10.1007/978-3-030-47701-1_13
Graf, I., Willeit, M., Kasper, S. F., & Praschak-Rieder, N. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_6 · Cited by 1
Molecular imaging findings in bipolar disorder
Meyer, J. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819182-8.00016-8 · Cited by 1
Self-citation(2008) · Annals of the ICRP · doi:10.1016/j.icrp.2008.08.007
PET Chemistry: Radiopharmaceuticals
Roß, T. L., & Ametamey, S. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-65245-6_8
Characterization of [11C]DASB and [18F]FE-PE2I using microPET imaging in SERT and DAT knockout rats
Guerrin, C. G. J., Tesselaar, D. R. M., Zweistra, E. E., Cabiscol-Claveria, A., Janssen, B., Doorduin, J., Schellekens, A., Booij, J., & Homberg, J. R. (2025) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2025.109055 · Cited by 1
Bruzzone, S. E. P., Ozenne, B., Fisher, P. M., Ortega, G., Jensen, P. S., Dam, V. H., Svarer, C., Knudsen, G. M., Lesch, K., & Frokjaer, V. G. (2024) · Figshare · doi:10.6084/m9.figshare.26726351
Bruzzone, S. E. P., Ozenne, B., Fisher, P. M., Ortega, G., Jensen, P. S., Dam, V. H., Svarer, C., Knudsen, G. M., Lesch, K., & Frokjaer, V. G. (2024) · Figshare · doi:10.6084/m9.figshare.26726357
Bruzzone, S. E. P., Ozenne, B., Fisher, P. M., Ortega, G., Jensen, P. S., Dam, V. H., Svarer, C., Knudsen, G. M., Lesch, K., & Frokjaer, V. G. (2024) · Figshare · doi:10.6084/m9.figshare.26726354
Bruzzone, S. E. P., Ozenne, B., Fisher, P. M., Ortega, G., Jensen, P. S., Dam, V. H., Svarer, C., Knudsen, G. M., Lesch, K., & Frokjaer, V. G. (2024) · Figshare · doi:10.6084/m9.figshare.26726342
Bruzzone, S. E. P., Ozenne, B., Fisher, P. M., Ortega, G., Jensen, P. S., Dam, V. H., Svarer, C., Knudsen, G. M., Lesch, K., & Frokjaer, V. G. (2024) · Figshare · doi:10.6084/m9.figshare.26726348
Bruzzone, S. E. P., Ozenne, B., Fisher, P. M., Ortega, G., Jensen, P. S., Dam, V. H., Svarer, C., Knudsen, G. M., Lesch, K., & Frokjaer, V. G. (2024) · Figshare · doi:10.6084/m9.figshare.26726345
Bruzzone, S. E. P., Ozenne, B., Fisher, P. M., Ortega, G., Jensen, P. S., Dam, V. H., Svarer, C., Knudsen, G. M., Lesch, K., & Frokjaer, V. G. (2024) · Figshare · doi:10.6084/m9.figshare.26726339
Bruzzone, S. E. P., Ozenne, B., Fisher, P. M., Ortega, G., Jensen, P. S., Dam, V. H., Svarer, C., Knudsen, G. M., Lesch, K., & Frokjaer, V. G. (2024) · Figshare · doi:10.6084/m9.figshare.26726336
Bruzzone, S. E. P., Ozenne, B., Fisher, P. M., Ortega, G., Jensen, P. S., Dam, V. H., Svarer, C., Knudsen, G. M., Lesch, K., & Frokjaer, V. G. (2024) · Figshare · doi:10.6084/m9.figshare.26726360
Conception de nouveaux agents iodés pour l'imagerie TEMP des récepteurs 5-HT4
Babin, V. (2018) · theses.fr (ABES) · doi:10.70675/78ed811azf823z4546za3d9z9163f82223df · Cited by 1
BindingDB (2009) · UC San Diego · doi:10.7270/q2b27tzj
BindingDB (2012) · UC San Diego · doi:10.7270/q2qz28j1
BindingDB (2023) · UC San Diego · doi:10.7270/q26m3bs8
BindingDB (2009) · UC San Diego · doi:10.7270/q2154gg7
Metadata
- Authors
- Houle, S., Ginovart, N., Hussey, D., Meyer, J. H., & Wilson, A. A.
- Affiliations
- Centre for Addiction and Mental Health (CA)
- Corresponding author
- Houle, S.
- Venue
- European Journal of Nuclear Medicine
- Published
- 2000-09-23
- Volume
- 27
- Issue
- 11
- Pages
- 1719-1722
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2169396775
- Cited by
- 276
- References
- 8
- Citations by year
- 2025: 3 · 2024: 4 · 2023: 2 · 2022: 4 · 2021: 3 · 2020: 14 · 2019: 7 · 2018: 6 · 2017: 10 · 2016: 10 · 2015: 8 · 2014: 13 · 2013: 7 · 2012: 11
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- serotonin transporter, [11C]DASB, serotonin uptake, neuroimaging, radiotracer metabolism, citalopram, dopamine transporter, norepinephrine transporter, brain penetration
- MeSH terms
- Adult, Benzylamines, Carbon Radioisotopes, Carrier Proteins, Female, Humans, Male, Membrane Glycoproteins, Middle Aged, Nerve Tissue Proteins, Tomography, Emission-Computed, Membrane Transport Proteins, Serotonin Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.